# Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine

> **NCT06060782** · PHASE1 · RECRUITING · sponsor: **Fifth Affiliated Hospital, Sun Yat-Sen University** · enrollment: 28 (estimated)

## Conditions studied

- Burkitt Lymphoma
- Lymphoblastic Lymphoma, Adult
- Acute Lymphoblastic Leukemia, Adult

## Interventions

- **DRUG:** Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen

## Key facts

- **NCT ID:** NCT06060782
- **Lead sponsor:** Fifth Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-06
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06060782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06060782, "Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06060782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*